ASCO 2022 Conference Coverage


 

ASCO 2022 Survival Outcomes in Metastatic HR+, HER2- IDC Compared to ILC and Mixed Ductal/Lobular Treated With ET in Combination With CDK4/6is/mTORi/PI3Ki

802 views
June 9, 2022
Comments 0
Login to view comments. Click here to Login